- Eli Lilly's (LLY +4%) Ramucirumab met the main goal of a Phase III study of patients with second-line non-small cell lung cancer (NSCLC) by improving survival rates compared with a placebo.
- Ramucirumab and the placebo were administered in combination with the chemotherapy Docetaxel.
- Ramucirumab also showed a statistically significant improvement in progression-free survival. (PR)
Eli Lilly lung-cancer drug meets goal of Phase III study
Feb 19 2014, 08:26 ET